Adenoid cystic cancer of nasopharynx: a single-institution retrospective study
Open Access
- 9 June 2026
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 16 (1) , 27-37
Abstract
Introduction. Adenocystic nasopharyngeal carcinoma is a rare but highly aggressive malignancy arising from the tissue of the minor salivary glands. Currently, there is no consensus in the medical community regarding the optimal treatment method. The priority of surgery over radiation therapy, as well as the advisability of monotherapy versus combination approaches, remain controversial. Aim. To summarize the clinical characteristics of adenocystic nasopharyngeal carcinoma based on an analysis of 13 cases from a single institution, with the aim of optimizing therapeutic approaches for treating patients with these rare tumors. Materials and methods. A retrospective analysis of data from 13 patients with nasopharyngeal adenocarcinoma treated at the N. N. Blokhin National Medical Research Center of Oncology from 1989 to 2023 was conducted. All patients underwent conservative chemoradiation therapy: in 6 cases – concurrent chemoradiation therapy, in 7 cases – induction chemotherapy followed by radiation or chemoradiation. Results. A complete clinical effect was achieved in 9 patients, a partial effect in 4. Disease progression was noted in 7 cases: local recurrence in 3 patients, continued tumor growth in 1, distant metastases in 3. The five-year survival rate was 38.5 %. Five patients died during the first two months, another three were lost to follow-up 5–15 months after the start of treatment. The median overall survival was 28 months. Conclusion. Adenoid cystic carcinoma of the nasopharynx is an extremely rare pathology. Although the standard treatment is surgery followed by radiation therapy, when radical surgery is not possible in patients with locally advanced disease, chemoradiation therapy becomes the treatment of choice.Keywords
This publication has 37 references indexed in Scilit:
- Adenoid cystic carcinoma: insights from molecular characterization and therapeutic advancesMedcomm, 2024
- A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)Contemporary Clinical Trials Communications, 2019
- Endoscopic endonasal resection of sinonasal/anterior skull base malignancy (Kadish C esthesioneuroblastoma)Acta Neurochirurgica, 2017
- Cervical Lymph Node Metastasis in High-Grade Transformation of Head and Neck Adenoid Cystic Carcinoma: A Collective International ReviewAdvances in Therapy, 2016
- Management of Nasopharyngeal Adenoid Cystic CarcinomaJournal of Oral and Maxillofacial Surgery, 2013
- Concurrent chemoradiation for adenoid cystic carcinoma of the head and neckHead & Neck, 2011
- Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinomaBritish Journal of Oral and Maxillofacial Surgery, 2011
- Proton Beam Radiation Therapy for Skull Base Adenoid Cystic CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2006
- Cylindroma of the nasopharynx: A chronic diseaseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1986